ALB and hepatocellular carcinoma: developed an HCC risk prediction model (age‐albumin‐sex‐liver cirrhosis‐HCC [AASL‐HCC] scoring system) for a cohort of 1242 patients with CHB treated with entecavir (ETV)/tenofovir disoproxil fumarate (TDF) in Korea, which had a C‐statistic of 0.802 (95% CI: 0.716–0.888) [27].